Upcoming Conference Participations, Cash Dividends, and Share Price Movements - Research Report on Johnson & Johnson, Boston Scientific, NuVasive, Exelixis, and Healthways

Editor Note: For more information about this release, please scroll to bottom

Jan 07, 2014, 08:00 ET from Analysts' Corner

NEW YORK, January 7, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Boston Scientific Corporation (NYSE: BSX), NuVasive, Inc. (NASDAQ: NUVA), Exelixis, Inc. (NASDAQ: EXEL), and Healthways Inc. (NASDAQ: HWAY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On January 2, 2014, Johnson & Johnson announced that its Board of Directors has declared Q1 2014 cash dividend of $0.66 per share on the Company's common stock. Johnson & Johnson added that the dividend is payable on March 11, 2014 to shareholders of record at the close of business on February 25, 2014, with the ex-dividend date of February 21, 2014. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Boston Scientific Corporation Research Report

On January 2, 2014, Boston Scientific Corporation (Boston Scientific) announced that the Company will participate in the upcoming 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 in San Francisco. The Company stated that Boston Scientific President and CEO, Mike Mahoney, will present about the Company beginning at approximately 9:00 a.m. PT, following which, Dan Brennan, Executive Vice President and CFO, and Keith Dawkins, M.D., Executive Vice President and Global Chief Medical Officer, will join Mr. Mahoney in a question and answer session. Boston Scientific added that a live webcast of the presentation and question and answer session can be accessed through its website. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5640_BSX

--

NuVasive, Inc. Research Report

On December 30, 2013, NuVasive, Inc. (NuVasive) announced that Chairman of the Board and CEO, Alex Lukianov, is scheduled to present at the J.P. Morgan Healthcare Conference in San Francisco, California on January 15, 2014 at 9:00 a.m. PST. The Company added that a live webcast of the presentation can be accessed via the Investor Relations page of the Company's website, where a replay of the presentation will also remain available for 30 days. The Full Research Report on NuVasive, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c66c_NUVA

--

Exelixis, Inc. Research Report

On January 2, 2014, Exelixis, Inc.'s (Exelixis) stock rose 0.82%, ending the day at $6.18. Over the previous three trading sessions, shares of Exelixis increased 4.22%, compared to the Nasdaq Composite, which declined 0.33% during the same period. The Full Research Report on Exelixis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73be_EXEL

--

Healthways Inc. Research Report

On January 2, 2014, Healthways Inc. (Healthways) announced that the Company will participate in the 32nd Annual J.P. Morgan Healthcare Conference to be held from January 13, 2014 to January 16, 2014 in San Francisco. The Company stated that its President and CEO, Ben R. Leedle, Jr., is scheduled to present at the conference on January 14, 2014 at 6:00 p.m. EST (3:00 p.m. PST). Healthways added that the presentation and its replay will be available online under the "Investors" section of its website. The Full Research Report on Healthways Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/76fd_HWAY

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner